159 related articles for article (PubMed ID: 35559799)
1. Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions.
Jenei K; Burgess M; Peacock S; Raymakers AJN
J Cancer Policy; 2021 Dec; 30():100303. PubMed ID: 35559799
[TBL] [Abstract][Full Text] [Related]
2. Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design.
Fyfe R; Anstis O; Kapadia K; Jordan M; Sword DO; Weinkove R
BMJ Open; 2024 Jan; 14(1):e071112. PubMed ID: 38262637
[TBL] [Abstract][Full Text] [Related]
3. Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial.
Castillo G; Lalu MM; Asad S; Foster M; Kekre N; Fergusson DA; Hawrysh T; Atkins H; Thavorn K; Montroy J; Schwartz S; Holt RA; Broady R; Presseau J
BMJ Open; 2021 Mar; 11(3):e043929. PubMed ID: 33741670
[TBL] [Abstract][Full Text] [Related]
4. A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams.
Stenson CL; Vidrine J; Dewhurst F; Osborne W; Menne T; Stocker R
Palliat Med; 2023 Feb; 37(2):215-220. PubMed ID: 36428287
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials.
Raymakers AJN; Regier DA; Peacock SJ; Freeman CL
J Cancer Policy; 2021 Dec; 30():100304. PubMed ID: 35559800
[TBL] [Abstract][Full Text] [Related]
6. Characterizing Social Media Messages Related to Underage JUUL E-Cigarette Buying and Selling: Cross-Sectional Analysis of Reddit Subreddits.
Liu H; Li Q; Zhan Y; Zhang Z; Zeng DD; Leischow SJ
J Med Internet Res; 2020 Jul; 22(7):e16962. PubMed ID: 32706661
[TBL] [Abstract][Full Text] [Related]
7. An Examination of Patients and Caregivers on Reddit Navigating Brain Cancer: Content Analysis of the Brain Tumor Subreddit.
Tripathi SD; Parker PD; Prabhu AV; Thomas K; Rodriguez A
JMIR Cancer; 2022 Jun; 8(2):e35324. PubMed ID: 35731559
[TBL] [Abstract][Full Text] [Related]
8. Oncology nurse competency in chimeric antigen receptor T-cell therapy: A qualitative study.
He J; Li J; Feng LN; Feng LX; Qiang W; Wang W; Dong L
Nurse Educ Today; 2024 Jan; 132():106040. PubMed ID: 37956569
[TBL] [Abstract][Full Text] [Related]
9. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
10. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S
Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
12. Access to CAR T-cell therapy: Focus on diversity, equity and inclusion.
Odstrcil MS; Lee CJ; Sobieski C; Weisdorf D; Couriel D
Blood Rev; 2024 Jan; 63():101136. PubMed ID: 37863793
[TBL] [Abstract][Full Text] [Related]
13. Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
Snyder S; Chung KC; Jun MP; Gitlin M
Adv Ther; 2021 Sep; 38(9):4659-4674. PubMed ID: 34302277
[TBL] [Abstract][Full Text] [Related]
14. Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis.
Booth A; Bell T; Halhol S; Pan S; Welch V; Merinopoulou E; Lambrelli D; Cox A
J Med Internet Res; 2019 Nov; 21(11):e14285. PubMed ID: 31755871
[TBL] [Abstract][Full Text] [Related]
15. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
16. Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy.
Wilson M; Thavorn K; Hawrysh T; Graham ID; Atkins H; Kekre N; Coyle D; Lalu MM; Fergusson DA; Chan KK; Ollendorf DA; Presseau J
BMJ Open; 2021 Aug; 11(8):e046707. PubMed ID: 34385243
[TBL] [Abstract][Full Text] [Related]
17. Thoughts and Experiences of Behçet Disease From Participants on a Reddit Subforum: Qualitative Online Community Analysis.
Li JX; Yacyshyn E
JMIR Form Res; 2023 Dec; 7():e49380. PubMed ID: 38085563
[TBL] [Abstract][Full Text] [Related]
18. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
[TBL] [Abstract][Full Text] [Related]
19. Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
Snyder S; Albertson T; Garcia J; Gitlin M; Jun MP
Adv Ther; 2021 Aug; 38(8):4541-4555. PubMed ID: 34279805
[TBL] [Abstract][Full Text] [Related]
20. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
